Výsledky vyhledávání - "Patricia R. Wigle"

Akademický článek

Metabolic and Bariatric Surgery Utilization Trends in the United States: Evidence From 2012 to 2021 National Electronic Medical Records Network

Autor: Abdulrahman Alsuhibani, PharmD, MSc, PhD, Jonathan R. Thompson, MD, FACS, FASMBS, Patricia R. Wigle, PharmD, BCPS, BCACP, FCCP, Jeff Jianfei Guo, BPharm, PhD, Alex C. Lin, MS, PhD, Marepalli B. Rao, MS, PhD, Ana L. Hincapie, MS, PhD

Publikováno v: Annals of Surgery Open, Vol 4, Iss 4, p e317 (2023)

Background:. Bariatric surgery has evolved over the past 2 decades yet assessing trends of bariatric surgery utilization in the growing eligible population is lacking. Aim:. This study aimed to update the trends in bariatric surgery utilization, chan

Externí odkaz: https://doaj.org/article/368034fd849449a0967f57926d63a9a3

Zobrazit plný text záznamu

Akademický článek

Safety reporting of Essure medical device: a qualitative and quantitative assessment on the FDA manufacturer and user facility device experience database in 2018

Autor: Chenyu Zou, Brandy Davis, Patricia R. Wigle, Ana L. Hincapie, Jeff Jianfei Guo

Publikováno v: Frontiers in Reproductive Health, Vol 5 (2023)

BackgroundThere have been numerous cases of adverse events since the introduction of Essure medical devices for sterilization in 2002. This study analyzed the safety event reports of the Essure reported in the Manufacturer and User Facility Device Ex

Externí odkaz: https://doaj.org/article/f40a6e06570f48589ae6becb595e5e47

Zobrazit plný text záznamu

The Utilization, Expenditure, and Price of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the US Medicaid Programs: Trends Over a 31 Year Period

Autor: Rawan O. Almadfaa, Patricia R. Wigle, Ana L. Hincapie, Jeff J. Guo

Publikováno v: International journal of cardiology. 370

Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are used for several indications including hypertension. Our aim is to evaluate the utilization, expenditure, and drug price of ACEIs and ARBs in the US Medicai

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6959b97172f8a986e0922a283ebe3cf5
https://pubmed.ncbi.nlm.nih.gov/36306953

Zobrazit plný text záznamu

Comparative effectiveness and persistence of TNFi and non-TNFi in juvenile idiopathic arthritis: a large paediatric rheumatology centre in the USA

Autor: Jeff J. Guo, Yuxiang Li, Daniel J. Lovell, Patricia R. Wigle, Bin Huang, Ana L. Hincapie, Esi M. Morgan, X. Yue, Tingting Qiu

Publikováno v: Rheumatology. 60:4063-4073

Objective To evaluate the persistence and effectiveness of TNF inhibitors (TNFi) vs non-TNFi among newly diagnosed JIA patients after initiation of biologic DMARD (bDMARD). Methods Using longitudinal patient-level data extracted from electronic medic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2b0a0449f55929c2fae3f94688d897a
https://doi.org/10.1093/rheumatology/keaa877

Zobrazit plný text záznamu

Off-label medication use in rare pediatric diseases in the United States

Autor: Jeff J. Guo, X. Yue, Patricia R. Wigle, Albert Fung

Publikováno v: Intractable Rare Dis Res

Many pediatric patients with rare diseases use drugs off-label due to limited data in pediatric patients. Off-label treatment remains an important public health issue for neonates, infants, children, and adolescents, especially for pediatric patients

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64ac697801486d383240d948426d46d8
https://pubmed.ncbi.nlm.nih.gov/34877235

Zobrazit plný text záznamu

Correction to: Prescribing Patterns and Impact of Factors Associated with Time to Initial Biologic Therapy among Children with Non-systemic Juvenile Idiopathic Arthritis

Autor: Bin Huang, Jeff J. Guo, Ana L. Hincapie, X. Yue, Yuxiang Li, Patricia R. Wigle, Esi M. Morgan, Tingting Qiu

Publikováno v: Pediatric Drugs.

The aim of this study was to examine patterns of initial prescriptions, investigate time to initiation of biologic disease-modifying anti-rheumatic drugs (bDMARDs), and evaluate the impact of clinical and other baseline factors associated with the ti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0f77f3c602a9c77f36c8de6d9e8f33e2
https://doi.org/10.1007/s40272-021-00447-1

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání